Cargando…

Myelofibrosis at diagnosis is associated with the failure of treatment-free remission in CML patients

The management of patients with chronic myeloid leukemia (CML) has been revolutionized by the introduction of tyrosine kinase inhibitors (TKIs), which induce deep molecular responses so that treatment can eventually be discontinued, leading to treatment-free remission (TFR) in a subset of patients....

Descripción completa

Detalles Bibliográficos
Autores principales:	Jacobi, Henrike, Vieri, Margherita, Bütow, Marlena, Namasu, Carolina Y., Flüter, Laura, Costa, Ivan G., Maié, Tiago, Lindemann-Docter, Katharina, Chatain, Nicolas, Beier, Fabian, Huber, Michael, Wagner, Wolfgang, Crysandt, Martina, Brümmendorf, Tim H., Schemionek, Mirle
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10352620/ https://www.ncbi.nlm.nih.gov/pubmed/37469867 http://dx.doi.org/10.3389/fphar.2023.1212392

Ejemplares similares

P653: CML LONG-TERM LEUKEMIC STEM CELL PERSISTENCE IS INFLUENCED BY MYELOFIBROSIS AT DIAGNOSIS
por: Jacobi, Henrike, et al.
Publicado: (2023)

Targeting cytokine-induced leukemic stem cell persistence in chronic myeloid leukemia by IKK2-inhibition
por: Bütow, Marlena, et al.
Publicado: (2022)

Therapeutic inhibition of FcγRIIb signaling targets leukemic stem cells in chronic myeloid leukemia
por: Parting, Oliver, et al.
Publicado: (2020)

The SCLtTAxBCR-ABL transgenic mouse model closely reflects the differential effects of dasatinib on normal and malignant hematopoiesis in chronic phase-CML patients
por: Schubert, Claudia, et al.
Publicado: (2017)

Eltrombopag Preserves the Clonogenic Potential of Hematopoietic Stem Cells During Treatment With Antithymocyte Globulin in Patients With Aplastic Anemia
por: Vieri, Margherita, et al.
Publicado: (2023)

Mast cell deficiency prevents BCR::ABL1 induced splenomegaly and cytokine elevation in a CML mouse model
por: Langhammer, Melanie, et al.
Publicado: (2023)

Infliximab therapy together with tyrosine kinase inhibition targets leukemic stem cells in chronic myeloid leukemia
por: Herrmann, Oliver, et al.
Publicado: (2019)

Differential roles of STAT1 and STAT2 in the sensitivity of JAK2V617F- vs. BCR-ABL-positive cells to interferon alpha
por: Schubert, Claudia, et al.
Publicado: (2019)

Calreticulin-mutant proteins induce megakaryocytic signaling to transform hematopoietic cells and undergo accelerated degradation and Golgi-mediated secretion
por: Han, Lijuan, et al.
Publicado: (2016)

XBP1 promotes NRAS(G12D) pre‐B acute lymphoblastic leukaemia through IL‐7 receptor signalling and provides a therapeutic vulnerability for oncogenic RAS
por: Salimi, Azam, et al.
Publicado: (2023)

Combined inhibition of BCR-ABL1 and the proteasome as a potential novel therapeutic approach in BCR-ABL positive acute lymphoblastic leukemia
por: Maletzke, Saskia, et al.
Publicado: (2022)

Intracellular Retention of ABL Kinase Inhibitors Determines Commitment to Apoptosis in CML Cells
por: Lipka, Daniel B., et al.
Publicado: (2012)

The Unfolded Protein Response Is a Major Driver of LCN2 Expression in BCR–ABL- and JAK2V617F-Positive MPN
por: Tillmann, Stefan, et al.
Publicado: (2021)

A phase I first-in-man study to investigate the pharmacokinetics and safety of liposomal dexamethasone in patients with progressive multiple myeloma
por: Metselaar, Josbert, et al.
Publicado: (2023)

Treatment-Free Remission: the New Goal in CML Therapy
por: Atallah, Ehab, et al.
Publicado: (2021)

Dissecting Genomic Aberrations in Myeloproliferative Neoplasms by Multiplex-PCR and Next Generation Sequencing
por: Kirschner, Martin M. J., et al.
Publicado: (2015)

Is Allogeneic Transplantation an Option in Patients Affected by Concurrent Myelofibrosis and Chronic Myeloid Leukemia (CML)?
por: Sora, Federica, et al.
Publicado: (2021)

Targeting autophagy increases the efficacy of proteasome inhibitor treatment in multiple myeloma by induction of apoptosis and activation of JNK
por: Salimi, Azam, et al.
Publicado: (2022)

CXorf48 is a potential therapeutic target for achieving treatment-free remission in CML patients
por: Matsushita, M, et al.
Publicado: (2017)

Incidences of Deep Molecular Responses and Treatment-Free Remission in de Novo CP-CML Patients
por: Etienne, Gabriel, et al.
Publicado: (2020)

Treatment-free remission: A new goal for all chronic phase (CP)-CML patients
por: Rea, Delphine
Publicado: (2018)

The Bone Marrow Immune Microenvironment in CML: Treatment Responses, Treatment-Free Remission, and Therapeutic Vulnerabilities
por: Patterson, Shaun David, et al.
Publicado: (2023)

Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IV
por: Saussele, Susanne, et al.
Publicado: (2018)

New Markers of Disease Progression in Myelofibrosis
por: Campanelli, Rita, et al.
Publicado: (2021)

Presence of TERT Promoter Mutations is a Secondary Event and Associates with Elongated Telomere Length in Myxoid Liposarcomas
por: Ventura Ferreira, Monica S., et al.
Publicado: (2018)

Heterogeneous bone-marrow stromal progenitors drive myelofibrosis via a druggable alarmin axis
por: Leimkühler, Nils B., et al.
Publicado: (2021)

Cytogenetic study in CML
por: Subramanian, P.G.
Publicado: (2012)

CML: Evolution and design
por: Murray-Rust, Peter, et al.
Publicado: (2011)

Myelofibrosis
por: Passamonti, Francesco, et al.
Publicado: (2023)

Standard care and investigational drugs in the treatment of myelofibrosis
por: Barraco, Daniela, et al.
Publicado: (2019)

Comparable Effects of the Androgen Derivatives Danazol, Oxymetholone and Nandrolone on Telomerase Activity in Human Primary Hematopoietic Cells from Patients with Dyskeratosis Congenita
por: Vieri, Margherita, et al.
Publicado: (2020)

Identification of the Adapter Molecule MTSS1 as a Potential Oncogene-Specific Tumor Suppressor in Acute Myeloid Leukemia
por: Schemionek, Mirle, et al.
Publicado: (2015)

Impaired Overall Survival in Young Patients With Acute Myeloid Leukemia and Variants in Genes Predisposing for Myeloid Malignancies
por: Kirschner, Martin, et al.
Publicado: (2022)

A folate receptor 3 SNP promotes mitochondria‐induced clonogenicity of CML leukemia cells: Implications for treatment free remission
por: Shen, Na, et al.
Publicado: (2021)

Acute Myeloid Leukemia Transformation from Myelofibrosis Upon Remission of an Orbital Myeloid Sarcoma – A Case Report
por: Chen, Nancy, et al.
Publicado: (2021)

Evidence that Prefibrotic Myelofibrosis Is Aligned along a Clinical and Biological Continuum Featuring Primary Myelofibrosis
por: Barosi, Giovanni, et al.
Publicado: (2012)

KIT D816V Mast Cells Derived from Induced Pluripotent Stem Cells Recapitulate Systemic Mastocytosis Transcriptional Profile
por: de Toledo, Marcelo A. S., et al.
Publicado: (2023)

P804: EX VIVO TREATMENT WITH ELTROMBOPAG RESCUES HEMATOPOIETIC STEM CELLS FROM ANTI-THYMOCYTE GLOBULIN-RELATED DAMAGE DURING IMMUNOSUPPRESSIVE THERAPY IN PATIENTS WITH APLASTIC ANEMIA
por: Vieri, M., et al.
Publicado: (2022)

Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants
por: Hehlmann, R, et al.
Publicado: (2017)

New concepts for CML clonality
por: Khorashad, Jamshid S., et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_gvi5252tu2eapkof44737gkjuv